In today’s Extraordinary Shareholders’ Meeting of Vivalis held in Nantes, France, all resolutions were approved by its shareholders. A majority of 99.1% of the represented share capital voted in favor of the merger to create Valneva SE, a biotech leader in vaccines and antibodies. A total of approximately 70% of the outstanding share capital of Vivalis SA was represented in the shareholders meeting.
As previously announced, Intercell’s shareholder approved the proposed merger with Vivalis SA with a majority of 97.4% of the represented share capital.
Following the approvals of the both shareholders the merger is now only subject to completion of certain administrative steps and is expected to close in May 2013. Subject to the approval of the French market authorities, Valneva SE will launch a EUR 40 million capital increase shortly after the completion of the Merger.
Thomas Lingelbach, future President and Chief Executive Officer of Valneva and Franck Grimaud, future President and Chief Business Officer commented: “We are excited about the broad approval of the merger by our shareholders and are now heading towards closing in May 2013. Valneva will be a European biotech leader in vaccines and antibodies with complementing talents and capabilities, a broad portfolio of product candidates, diversified revenues and enhanced financial strength to fund its future growth.”